229 related articles for article (PubMed ID: 24493142)
1. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.
Qi WX; Shen Z; Tang LN; Yao Y
Clin Drug Investig; 2014 Apr; 34(4):231-40. PubMed ID: 24493142
[TBL] [Abstract][Full Text] [Related]
2. Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis.
Peng L; Bu Z; Zhou Y; Ye X; Liu J; Zhao Q
Tumour Biol; 2014 Sep; 35(9):9419-27. PubMed ID: 24957040
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis.
Zhang X; Ran Y; Shao Y; Wang K; Zhu Y
Br J Clin Pharmacol; 2016 Jan; 81(1):33-40. PubMed ID: 26331893
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.
Peng L; Zhao Q; Ye X; Zhou Y; Hu D; Zheng S
PLoS One; 2014; 9(11):e111839. PubMed ID: 25365378
[TBL] [Abstract][Full Text] [Related]
5. Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis.
Qi WX; Shen F; Qing Z; Xiao-Mao G
Tumour Biol; 2014 Nov; 35(11):10715-22. PubMed ID: 25070487
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.
Qi WX; Tang LN; Shen Z; Yao Y
Eur J Clin Pharmacol; 2014 Apr; 70(4):461-7. PubMed ID: 24390630
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
Qi WX; He AN; Shen Z; Yao Y
Br J Clin Pharmacol; 2013 Sep; 76(3):348-57. PubMed ID: 23617405
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
Qi WX; Fu S; Zhang Q; Guo XM
J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
Prescrire Int; 2014 Sep; 23(152):205. PubMed ID: 25325116
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
[TBL] [Abstract][Full Text] [Related]
17. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Br J Clin Pharmacol; 2013 Apr; 75(4):919-30. PubMed ID: 22882307
[TBL] [Abstract][Full Text] [Related]
19. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.
Wang Z; Xu J; Nie W; Huang G; Tang J; Guan X
Eur J Clin Pharmacol; 2014 Feb; 70(2):225-31. PubMed ID: 24150533
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Wu S; Chen JJ; Kudelka A; Lu J; Zhu X
Lancet Oncol; 2008 Feb; 9(2):117-23. PubMed ID: 18221915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]